Literature DB >> 8849232

GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin.

M Stieger1, P Angehrn, B Wohlgensinger, H Gmünder.   

Abstract

The sequence of the gyrase B subunit gene from Staphylococcus aureus strains resistant to the gyrase B subunit inhibitors cyclothialidine, coumermycin, and novobiocin has been determined. The residues altered in the resistant gyrase B subunits map to the ATP-binding region, suggesting that the drugs inhibit ATP binding and hydrolysis. The pattern of cross-resistances indicates that the detailed binding mode of the compounds differs.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8849232      PMCID： PMC163264     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  36 in total

1.  gyrB mutations which confer coumarin resistance also affect DNA supercoiling and ATP hydrolysis by Escherichia coli DNA gyrase.

Authors:  A Contreras; A Maxwell
Journal:  Mol Microbiol       Date:  1992-06       Impact factor: 3.501

2.  Crystal structure of an N-terminal fragment of the DNA gyrase B protein.

Authors:  D B Wigley; G J Davies; E J Dodson; A Maxwell; G Dodson
Journal:  Nature       Date:  1991-06-20       Impact factor: 49.962

3.  Preliminary crystallographic analysis of the ATP-hydrolysing domain of the Escherichia coli DNA gyrase B protein.

Authors:  A P Jackson; A Maxwell; D B Wigley
Journal:  J Mol Biol       Date:  1991-01-05       Impact factor: 5.469

4.  4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction.

Authors:  M Oram; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 5.  Structure-activity relationships in DNA gyrase inhibitors.

Authors:  S Rádl
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

Review 6.  Inhibitors of DNA gyrase.

Authors:  K Drlica; S Coughlin
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

7.  Characterization of a gyrB mutation responsible for low-level nalidixic acid resistance in Neisseria gonorrhoeae.

Authors:  D C Stein; R J Danaher; T M Cook
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

8.  An unusual mechanism for resistance to the antibiotic coumermycin A1.

Authors:  I del Castillo; J L Vizán; M C Rodríguez-Sáinz; F Moreno
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

Review 9.  DNA gyrase: structure and function.

Authors:  R J Reece; A Maxwell
Journal:  Crit Rev Biochem Mol Biol       Date:  1991       Impact factor: 8.250

10.  Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins.

Authors:  E E Margerrison; R Hopewell; L M Fisher
Journal:  J Bacteriol       Date:  1992-03       Impact factor: 3.490
View more
  15 in total

1.  Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.

Authors:  Trudy H Grossman; Douglas J Bartels; Steve Mullin; Christian H Gross; Jonathan D Parsons; Yusheng Liao; Anne-Laure Grillot; Dean Stamos; Eric R Olson; Paul S Charifson; Nagraj Mani
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Adaptive acquisition of novobiocin resistance in Pasteurella multocida strains of avian origin.

Authors:  M Arif; F R Champlin
Journal:  Vet Res Commun       Date:  1998-11       Impact factor: 2.459

3.  Identification of an auxiliary druggable pocket in the DNA gyrase ATPase domain using fragment probes.

Authors:  Xiaojie Huang; Junsong Guo; Qi Liu; Qiong Gu; Jun Xu; Huihao Zhou
Journal:  Medchemcomm       Date:  2018-07-04       Impact factor: 3.597

4.  Brachyspira (Serpulina) hyodysenteriae gyrB mutants and interstrain transfer of coumermycin A(1) resistance.

Authors:  T B Stanton; E G Matson; S B Humphrey
Journal:  Appl Environ Microbiol       Date:  2001-05       Impact factor: 4.792

5.  In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class.

Authors:  Nagraj Mani; Christian H Gross; Jonathan D Parsons; Brian Hanzelka; Ute Müh; Steve Mullin; Yusheng Liao; Anne-Laure Grillot; Dean Stamos; Paul S Charifson; Trudy H Grossman
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.

Authors:  Michael D Huband; Patricia A Bradford; Linda G Otterson; Gregory S Basarab; Amy C Kutschke; Robert A Giacobbe; Sara A Patey; Richard A Alm; Michele R Johnstone; Marie E Potter; Paul F Miller; John P Mueller
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

7.  Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.

Authors:  B Fournier; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

8.  Accumulation of mutations in both gyrB and parE genes is associated with high-level resistance to novobiocin in Staphylococcus aureus.

Authors:  Mika Fujimoto-Nakamura; Hideaki Ito; Yoshihiro Oyamada; Takeshi Nishino; Jun-Ichi Yamagishi
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

9.  Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance.

Authors:  Christian H Gross; Jonathan D Parsons; Trudy H Grossman; Paul S Charifson; Steven Bellon; James Jernee; Maureen Dwyer; Stephen P Chambers; William Markland; Martyn Botfield; Scott A Raybuck
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

10.  Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.

Authors:  Neil R Stokes; Helena B Thomaides-Brears; Stephanie Barker; James M Bennett; Joanne Berry; Ian Collins; Lloyd G Czaplewski; Vicki Gamble; Paul Lancett; Alastair Logan; Christopher J Lunniss; Hilary Peasley; Stéphanie Pommier; Daniel Price; Carol Smee; David J Haydon
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.